LIV Emles at Home ETF

Samaritan Pharmaceuticals, Inc. (AMEX:LIV), a developer of innovative drugs, announced today the welcoming of Dr. Pauline S. Nys, a distinguished leader and innovator in the field of anticancer and cardiovascular drug development, to its Scientific Advisory board. Dr. Nys was a Full Professor of Biotechnology at the Research Center for Antibiotics, in Moscow, Russia. Presently, she serves as a Scientific Advisor to a few European and US biotechnological companies. Dr. Nys has published more than 100 articles in international scientific journals, as well as presenting numerous professional papers at scientific meetings. In addition, she is the author of more than 25 patents for biologically active compound production. Dr. Greeson, CEO of Samaritan, stated, "We are delighted to be able to rely on Dr. Nys' expertise in Cancer and Cardiovascular drug development; she really is a remarkable woman." Samaritan Pharmaceuticals: "We LIV....to Save Lives." Samaritan is a small-cap Biotech, driven to discover, develop, and commercialize innovative therapeutics for AIDS, Alzheimer's, Cancer and Heart disease. Look at www.samaritanpharma.com.